Biotech Startups

Synbiote was a biomaterials discovery lab spun out of the University of New South Wales that researched naturally occurring, bio-based polymers to replace non-renewable materials in industrial applications. Its work produced Biota360, a biopolymer electrolyte for solid-state batteries, before the research cycle concluded in 2025.

2 investors

Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.

2 investors

Artis BioSolutions is an integrated platform for genetic medicine that produces enzymatically synthesized synthetic DNA and develops it into clinical-grade advanced therapies with in-house GMP manufacturing. It serves developers of advanced therapy medicinal products across modalities such as mRNA, gene editing, viral vectors, cell therapies, and vaccines, with production sites in Watertown, MA (US) and Bilbao, Spain (EU).

2 investors

Synkrino Biotherapeutics develops SATIS, an AI-based system for drug discovery. The company operates in the biotechnology sector.

2 investors

Synplexity produces large-scale, cost-effective gene libraries for synthetic biology applications using microreactor technology. The company serves researchers in drug discovery, protein engineering, and functional screening across life sciences and biotechnology.

2 investors

Synplogen is a synthetic biology startup spun out of Kobe University that offers custom artificial gene synthesis and DNA library construction services using its proprietary OGAB and Combinatorial-OGAB (Combi-OGAB) DNA assembly methods. It also operates a gene-therapy biofoundry that designs, develops, and analyzes gene-therapy products such as viral vectors, including CMC development work.

2 investors

SynsoryBio develops protein-based drugs that detect their location in the body and activate only at diseased tissue, with applications across cancer and autoimmune conditions.

2 investors

SynThera develops bioactive glass-based biomaterials and specialty glass products for healthcare, industrial, and consumer applications including bone tissue regeneration, dental repair, skincare, and technical glass for electronics and aerospace. The company serves pharmaceutical, medical device, cosmetics, FMCG, and industrial sectors with a focus on high-purity glass materials.

2 investors

SynVaccine develops technology for the computer-aided design and construction of viral genomes, applying synthetic and computational biology to create viral-based products such as vaccines and viral-based therapeutics. The company targets applications in human pharma and animal health.

2 investors

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism. Its pipeline includes ST-905, a dual M1/M4 agonist in Phase 1 for schizophrenia, and ST-901, an NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression.

2 investors

T-CURX is a venture-backed biotechnology company developing autologous CAR-T cell therapies using proprietary non-viral technologies, including in vivo and bedside-manufactured CAR-T approaches based on T cell-targeted LNP delivery of Sleeping Beauty transposon vectors. Its clinical pipeline targets cancers such as AML and CLL as well as cross-entity targets in hematological malignancies and solid tumors.

2 investors

Tabulous is an AI-powered experimental data platform for biotech companies that replaces legacy electronic lab notebooks and laboratory information management systems. The platform enables scientists to collect, organize, and analyze experimental data with minimal onboarding and vendor lock-in.

2 investors

Tactiva Therapeutics develops immuno-oncology treatments using adoptive cell therapy approaches for cancer patients. The company leverages innovative methods in T cell engineering and gene therapy to address metastatic and gynecological cancers.

2 investors

Tailor Bio develops targeted cancer therapies for tumors characterized by chromosomal instability, working in the field of precision oncology.

2 investors

Valo builds an AI-driven drug discovery and development platform that combines real-world human data, causal inference, statistical genetics, and predictive chemistry to identify disease targets and engineer small-molecule compounds. It applies closed-loop modeling and laboratory capabilities to advance lead compounds into drug candidates.

2 investors

TareBio operates a platform for developing personalized and population-level vaccines against cancer and infectious diseases by analyzing immune cells already responding to a disease and reverse-engineering the antigens that activate them. The company works in the biotechnology and vaccine development space.

2 investors

Circio is a biotech company developing circular RNA technology (circVec) to improve AAV gene therapy expression for the treatment of genetic diseases. It focuses on gene and cell therapy research applications.

2 investors

Unlocking post-translational protein modification using chemical biology and computational approaches to develop drugs for previously undruggable oncology targets.

2 investors

Tattva Bio is developing a biology-driven manufacturing platform that uses photosynthetic biological cells to grow high-performance industrial materials under ambient conditions. The company aims to reduce carbon emissions and resource depletion associated with conventional extractive, energy-intensive material production.

2 investors

TATUM bioscience develops biotech solutions, though the page provides limited detail on specific products or target markets.

2 investors

Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions. Its lead clinical program targets Rett syndrome, alongside a broader pipeline of CNS programs.

2 investors

The Biological Computing Co. uses living neurons to study how biological systems process information and applies those insights to improve AI model training and inference. It aims to build a new class of computing hardware that learns and adapts with lower time, energy, and training costs than silicon.

2 investors

Developing a scalable off-the-shelf allogeneic gamma delta T cell therapy platform.

2 investors

2 investors